Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery Vosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S. J., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., Azagury, D. E., Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery 2022

Abstract

The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.

View details for DOI 10.1016/j.soard.2022.07.002

View details for PubMedID 36028428